Are you surprised that BPAX hasn't been able to land a lucrative partnership for the drug yet given the large opportunity? Has there been any buzz on recent conference calls about any pending partnership? A tiny market cap (~$50 million) plus a potential big-selling drug is always an equation to pique my interest in a stock so I may take a closer look at this one.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.